Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its participation in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on November 11, 2022, at 1:40 p.m. ET. The event can be accessed via live webcast in the Investors & Media section of its website, with a replay available for 30 days post-presentation. Xilio focuses on developing tumor-activated immuno-oncology therapies, using its GPS platform to create biologics targeting the tumor microenvironment, aiming for enhanced anti-tumor activity. Key product candidates include XTX101 and XTX202.
- None.
- None.
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-activated product candidates, including its clinical-stage programs, XTX101, a tumor-activated anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-activated IL-2, as well as its earlier pipeline, including XTX301, a tumor-activated IL-12. For more information, please visit https://xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).
For Investor Inquiries:
Myles Clouston
Vice President, Investor Relations
investors@xiliotx.com
For Media Inquiries:
Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com
FAQ
What is Xilio Therapeutics participating in on November 11, 2022?
Where can I watch the Xilio Therapeutics presentation?
What time is Xilio Therapeutics' fireside chat scheduled for?
How long will the Xilio Therapeutics presentation be available to view?
What is the focus of Xilio Therapeutics?
